MYC and Miyoshi myopathy: Leflunomide downregulated MYC by inhibiting several tyrosine kinases, including the PIM family, and synergized in combination with lenalidomide, another IMiD used as standard therapy in MM, further decreasing MYC and causing MM growth inhibition both in vitro and in vivo[89].